Author name: Anna

RTFCCR at ESMO 2025: Advancing the Dialogue on Microbiome in Oncology October 28, 2025 Berlin, October 17-21, 2025 – The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) was proud to participate in the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin—a global gathering of oncology professionals, researchers, and advocates committed to transforming cancer care. RTFCCCR was thrilled to see …

RTFCCR at ESMO 2025: Advancing the Dialogue on Microbiome in Oncology Read More »

RTFCCR and MRA join forces in the fight against Melanoma September 26, 2025 The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and the Melanoma Research Alliance (MRA) are proud to announce a new joint Request for Proposals (RFP) for Team Science Awards to advance the early detection, diagnosis, and risk stratification of melanoma. This award …

RTFCCR and MRA joining forces for Melanoma Read More »

Innovation and Patient Advocacy at the World Conference on Lung Cancer 2025 in Barcelona September 18, 2025 Barcelona, September 6–9, 2025 — The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) proudly participated in the World Conference on Lung Cancer for the first time. This conference offered a valuable opportunity to learn about the latest developments …

Innovation and Patient Advocacy at the World Conference on Lung Cancer 2025 in Barcelona Read More »

Rising Tide Foundation for Clinical Cancer Research Continues Partnership with Blood Cancer United to Co-Fund ACT Grants September 12, 2025 Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is pleased to continue its collaboration with Blood Cancer United in co-funding Academic Clinical Trials (ACT) initiative – an investigator-initiated clinical trial program designed to address unmet …

RTFCCR Continues Partnership with Blood Cancer United to Co-Fund ACT Grants Read More »

Grantee Spotlight: SAKK 01/18 Trial Drives Change in Global Cancer Guidelines August 7, 2025 We’re proud to share a major milestone achieved by one of our completed grants: the “SAKK 01/18 trial: Reduced intensity radio-chemotherapy for stage IIA/B seminoma” has led to a significant update in the National Comprehensive Cancer Network (NCCN) guidelines (image 1). Led by Dr. …

Grantee Spotlight: SAKK 01/18 Trial Drives Change in Global Cancer Guidelines Read More »